The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).
 
Helen J. Ross
Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Halozyme (Inst); Merck (Inst); Spectrum Pharmaceuticals (Inst)
 
David E. Kozono
No Relationships to Disclose
 
James John Urbanic
Stock and Other Ownership Interests - Illumina; Ions Pharmaceuticals; Seagen
 
Terence Marques Williams
No Relationships to Disclose
 
Carter Dufrane
No Relationships to Disclose
 
Ilze Bara
Employment - Genentech/Roche
 
Mayank Gandhi
Employment - Genentech/Roche
Stock and Other Ownership Interests - Bristol-Myers Squibb; Merck; Neurocrine Biosciences
Travel, Accommodations, Expenses - Genentech/Roche
 
Katja Schulze
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
JaneMichelle Michelle Brockman
Employment - Genentech/Roche
 
Xiaofei F. Wang
No Relationships to Disclose
 
Junheng Gao
No Relationships to Disclose
 
Everett E. Vokes
Stock and Other Ownership Interests - Coordination Pharmaceuticals
Honoraria - Abbvie; Amgen; Ascendis Pharma (I); AstraZeneca; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Radius Health (I); Regeneron; Takeda (I)
Consulting or Advisory Role - Abbvie; Amgen; Ascendis Pharma (I); AstraZeneca; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Radius Health (I); Regeneron; Takeda (I)
Research Funding - Abbvie; Bristol-Myers Squibb; Celgene; Novartis
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Regeneron
 
Tom Stinchcombe
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; EMD Serono; Foundation Medicine; G1 Therapeutics; Genentech/Roche; Lilly; Novartis; Pfizer; Takeda
Research Funding - Advaxis (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Genentech/Roche (Inst); Merck (Inst); Regeneron (Inst); Takeda (Inst)